60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Neutral” Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research note issued to investors on Tuesday morning,Benzinga reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Wednesday, February 19th.

60 Degrees Pharmaceuticals Price Performance

SXTP stock opened at $1.92 on Tuesday. The company has a market cap of $14.14 million, a P/E ratio of -0.19 and a beta of 4.22. 60 Degrees Pharmaceuticals has a 1 year low of $1.78 and a 1 year high of $35.99. The stock’s fifty day moving average price is $0.97 and its 200-day moving average price is $1.13.

Insider Transactions at 60 Degrees Pharmaceuticals

In related news, CEO Geoffrey S. Dow bought 35,823 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average cost of $1.27 per share, with a total value of $45,495.21. Following the acquisition, the chief executive officer now owns 94,580 shares in the company, valued at $120,116.60. This trade represents a 60.97 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired 60,372 shares of company stock worth $76,975 in the last 90 days. 10.27% of the stock is currently owned by insiders.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.